Thomas K. Equels, CEO & President at AIM ImmunoTech Inc. (AIM), bought 60,110 shares at $0.18 ($11K) on 2024-11-20, disclosed to the SEC on 2024-11-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| AIM | BUY | 2026-09-16 | $5K | — | Filing → |
| AIM | BUY | 2026-09-15 | $1K | — | Filing → |
| AIM | BUY | 2025-06-16 | $824 | — | Filing → |